Table 3.
Studies evaluating allogeneic HCT in relapsed/refractory MCL (> 30 patients).
| Author (year) |
N | Conditioning | Median age (range) |
TRM/NRM (years) |
Relapse (years) |
OS (years) |
|---|---|---|---|---|---|---|
| Maris (2004) [74] |
33 | RIC | 53 (33–70) | 9% (2) | 16 % (2) | 65% (2) |
| Cook (2010) [75] |
70 | RIC | 52 (25–69) | 18% (3) | 65 % (5) | 37% (5) |
| Le Gouill (2012) [76] |
70 | RIC | 56 (33–67) | 32% (2) | 18 % (2) | 53% (2) |
| Hamadani* (2013) [73] |
202 | MAC (37%) RIC (63%) |
54 (27–69) 59 (42–75) |
38–43% (1) | 32–33% (3) | 25–30% (3) |
| Fenske** (2014) [68] |
88 | RIC | 58 (26–75) | 17% (1) | 38 % (5) | 31% (5) |
| Kruger (2014) [77] |
33 | MAC (21%) RIC (79%) |
59 (33–69) | 24% (5) | 15 % (5) | 73% (5) |
Abbreviations: MAC=myeloablative conditioning; NRM=non-relapse mortality; OS=Overall survival; RIC=reduced intensity conditioning. TRM= treatment-related mortality.
*
Included only patients with refractory disease.
**
Excluded patients with refractory disease.